+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Interleukin Inhibitors Market Size, Share & Trends Analysis Report by Type, Route Of Administration (SC, IV), Application (RA, Psoriasis, IBD, Asthma), End-use, Region, and Segment Forecasts, 2025-2030

  • PDF Icon

    Report

  • 100 Pages
  • October 2024
  • Region: Global
  • Grand View Research
  • ID: 6024576
Description Jump to:
The global interleukin inhibitors market size is expected to reach USD 72.2 billion by 2030, registering a CAGR of 17.3% from 2025 to 2030. This can be attributed to a strong pipeline with upcoming launches of late-stage pipeline drugs.

The therapeutic landscape in this market is becoming increasingly competitive, as drugs are compared in head-to-head trials to determine superiority in terms of safety, efficacy, and tolerance. For instance, UCB’s bimekizumab is currently under investigation in three such trials against Humira (trial name: BE SURE), Stelara (BE VIVID), and Cosentyx (BE RADIANT)-indicated for plaque psoriasis.

Furthermore, increasing investments on various clinical trials and strategic alliances between pharmaceutical companies and research organizations for development of novel molecules are few major contributors to interleukin inhibitors market growth. For instance, Genentech (F. Hoffmann-La Roche Ltd.) has collaborated with Massachusetts General Hospital for developing Actemra (tocilizumab) for the treatment of giant cell arteritis.

Rise in consumer awareness about various autoimmune diseases and their treatment options is anticipated to impel demand. For instance, Arthritis Ireland launched an awareness campaign for rheumatoid arthritis, educating the public about different treatment options and significance of early diagnosis. In addition, the European Federation of Crohn's & Ulcerative Colitis Association offers various initiatives to create awareness among patients suffering from Inflammatory Bowel Disease (IBD).

Interleukin Inhibitors Market Report Highlights

  • By application, the psoriatic segment leading the market and accounted for a share of 37.0% in 2024
  • In 2024, IL-23 inhibitors led the market with a revenue share of 27.5%, due to their efficacy in treating autoimmune diseases, such as psoriasis and IBD.
  • By type, IL-17 inhibitors are expected to witness a significant CAGR of 16.1% over the forecast period.
  • Asia Pacific is expected to exhibit the fastest regional growth over the forecast period, fueled by enhanced healthcare infrastructure and growing disposable incomes.
  • Despite the high price of IL-inhibitors, favorable reimbursement policies are likely to provide affordability and support market penetration.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments
  • Competitive Landscape: Explore the market presence of key players worldwide
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

The leading players in the Interleukin Inhibitors market include:

  • Novartis AG
  • AbbVie Inc.
  • Eli Lilly and Company
  • Regeneron Pharmaceuticals Inc.
  • Johnson & Johnson Services, Inc.
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca
  • Bausch Health Companies Inc.
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Route of Administration
1.2.3. Application
1.2.4. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Interleukin Inhibitors Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. Interleukin Inhibitors Market: Type Business Analysis
4.1. Type Market Share, 2024 & 2030
4.2. Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4. IL-1 Inhibitors
4.4.1. IL-1 Inhibitors Market, 2018 - 2030 (USD Million)
4.5. IL-2 Inhibitors
4.5.1. IL-2 Inhibitors Market, 2018 - 2030 (USD Million)
4.6. IL-5 Inhibitors
4.6.1. IL-5 Inhibitors Market, 2018 - 2030 (USD Million)
4.7. IL-6 Inhibitors
4.7.1. IL-6 Inhibitors Market, 2018 - 2030 (USD Million)
4.8. IL-17 Inhibitors
4.8.1. IL-17 Inhibitors Market, 2018 - 2030 (USD Million)
4.9. IL-23 Inhibitors
4.9.1. IL-23 Inhibitors Market, 2018 - 2030 (USD Million)
4.10. Others
4.10.1. Others Market, 2018 - 2030 (USD Million)
Chapter 5. Interleukin Inhibitors Market: Route of Administration Business Analysis
5.1. Route of Administration Market Share, 2024 & 2030
5.2. Route of Administration Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
5.4. Subcutaneous (SC)
5.4.1. Subcutaneous (SC) Market, 2018 - 2030 (USD Million)
5.5. Intravenous (IV)
5.5.1. Intravenous (IV) Market, 2018 - 2030 (USD Million)
Chapter 6. Interleukin Inhibitors Market: Application Business Analysis
6.1. Application Market Share, 2024 & 2030
6.2. Application Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
6.4. Rheumatoid Arthritis
6.4.1. Rheumatoid Arthritis Market, 2018 - 2030 (USD Million)
6.5. Psoriasis
6.5.1. Psoriasis Market, 2018 - 2030 (USD Million)
6.6. Inflammatory Bowel Disease (IBD)
6.6.1. Inflammatory Bowel Disease (IBD) Market, 2018 - 2030 (USD Million)
6.7. Asthma
6.7.1. Asthma Market, 2018 - 2030 (USD Million)
6.8. Others
6.8.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. Interleukin Inhibitors Market: End Use Business Analysis
7.1. End Use Market Share, 2024 & 2030
7.2. End Use Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
7.4. Hospitals
7.4.1. Hospitals Market, 2018 - 2030 (USD Million)
7.5. Specialty Clinics
7.5.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
7.6. Others
7.6.1. Others Market, 2018 - 2030 (USD Million)
Chapter 8. Interleukin Inhibitors Market: Regional Estimates & Trend Analysis by Type, Route of Administration, Application, and End Use
8.1. Regional Market Share Analysis, 2024 & 2030
8.2. Regional Market Dashboard
8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.4. North America
8.4.1. North America Interleukin Inhibitors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
8.4.2. U.S.
8.4.2.1. Key Country Dynamics
8.4.2.2. Regulatory Framework
8.4.2.3. Competitive Insights
8.4.2.4. U.S. Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.3. Canada
8.4.3.1. Key Country Dynamics
8.4.3.2. Regulatory Framework
8.4.3.3. Competitive Insights
8.4.3.4. Canada Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.4. Mexico
8.4.4.1. Key Country Dynamics
8.4.4.2. Regulatory Framework
8.4.4.3. Competitive Insights
8.4.4.4. Mexico Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5. Europe
8.5.1. Europe Interleukin Inhibitors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
8.5.2. UK
8.5.2.1. Key Country Dynamics
8.5.2.2. Regulatory Framework
8.5.2.3. Competitive Insights
8.5.2.4. UK Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.3. Germany
8.5.3.1. Key Country Dynamics
8.5.3.2. Regulatory Framework
8.5.3.3. Competitive Insights
8.5.3.4. Germany Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.4. France
8.5.4.1. Key Country Dynamics
8.5.4.2. Regulatory Framework
8.5.4.3. Competitive Insights
8.5.4.4. France Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.5. Italy
8.5.5.1. Key Country Dynamics
8.5.5.2. Regulatory Framework
8.5.5.3. Competitive Insights
8.5.5.4. Italy Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.6. Spain
8.5.6.1. Key Country Dynamics
8.5.6.2. Regulatory Framework
8.5.6.3. Competitive Insights
8.5.6.4. Spain Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.7. Norway
8.5.7.1. Key Country Dynamics
8.5.7.2. Regulatory Framework
8.5.7.3. Competitive Insights
8.5.7.4. Norway Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.8. Denmark
8.5.8.1. Key Country Dynamics
8.5.8.2. Regulatory Framework
8.5.8.3. Competitive Insights
8.5.8.4. Denmark Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.9. Sweden
8.5.9.1. Key Country Dynamics
8.5.9.2. Regulatory Framework
8.5.9.3. Competitive Insights
8.5.9.4. Sweden Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6. Asia Pacific
8.6.1. Asia Pacific Interleukin Inhibitors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
8.6.2. Japan
8.6.2.1. Key Country Dynamics
8.6.2.2. Regulatory Framework
8.6.2.3. Competitive Insights
8.6.2.4. Japan Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.3. China
8.6.3.1. Key Country Dynamics
8.6.3.2. Regulatory Framework
8.6.3.3. Competitive Insights
8.6.3.4. China Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.4. India
8.6.4.1. Key Country Dynamics
8.6.4.2. Regulatory Framework
8.6.4.3. Competitive Insights
8.6.4.4. India Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.5. South Korea
8.6.5.1. Key Country Dynamics
8.6.5.2. Regulatory Framework
8.6.5.3. Competitive Insights
8.6.5.4. South Korea Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.6. Australia
8.6.6.1. Key Country Dynamics
8.6.6.2. Regulatory Framework
8.6.6.3. Competitive Insights
8.6.6.4. Australia Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.7. Thailand
8.6.7.1. Key Country Dynamics
8.6.7.2. Regulatory Framework
8.6.7.3. Competitive Insights
8.6.7.4. Thailand Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.7. Latin America
8.7.1. Latin America Interleukin Inhibitors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
8.7.2. Brazil
8.7.2.1. Key Country Dynamics
8.7.2.2. Regulatory Framework
8.7.2.3. Competitive Insights
8.7.2.4. Brazil Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.7.3. Argentina
8.7.3.1. Key Country Dynamics
8.7.3.2. Regulatory Framework
8.7.3.3. Competitive Insights
8.7.3.4. Argentina Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8. MEA
8.8.1. MEA Interleukin Inhibitors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
8.8.2. South Africa
8.8.2.1. Key Country Dynamics
8.8.2.2. Regulatory Framework
8.8.2.3. Competitive Insights
8.8.2.4. South Africa Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key Country Dynamics
8.8.3.2. Regulatory Framework
8.8.3.3. Competitive Insights
8.8.3.4. Saudi Arabia Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8.4. UAE
8.8.4.1. Key Country Dynamics
8.8.4.2. Regulatory Framework
8.8.4.3. Competitive Insights
8.8.4.4. UAE Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key Country Dynamics
8.8.5.2. Regulatory Framework
8.8.5.3. Competitive Insights
8.8.5.4. Kuwait Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
9.5.1. Novartis AG
9.5.1.1. Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. AbbVie Inc.
9.5.2.1. Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. Eli Lilly and Company
9.5.3.1. Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. Regeneron Pharmaceuticals Inc.
9.5.4.1. Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. Johnson & Johnson Services, Inc.
9.5.5.1. Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. F. Hoffmann-La Roche Ltd
9.5.6.1. Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. AstraZeneca
9.5.7.1. Overview
9.5.7.2. Financial Performance
9.5.7.3. Product Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. Bausch Health Companies Inc.
9.5.8.1. Overview
9.5.8.2. Financial Performance
9.5.8.3. Product Benchmarking
9.5.8.4. Strategic Initiatives
9.5.9. GlaxoSmithKline plc
9.5.9.1. Overview
9.5.9.2. Financial Performance
9.5.9.3. Product Benchmarking
9.5.9.4. Strategic Initiatives
9.5.10. Teva Pharmaceutical Industries Ltd
9.5.10.1. Overview
9.5.10.2. Financial Performance
9.5.10.3. Product Benchmarking
9.5.10.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global interleukin inhibitors market, by region, 2018 - 2030 (USD Million)
Table 4 Global interleukin inhibitors market, by drug class, 2018 - 2030 (USD Million)
Table 5 Global interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 6 Global interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 7 North America interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 8 North America interleukin inhibitors market, by country, 2018 - 2030 (USD Million)
Table 9 North America interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 10 North America interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 11 North America interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 12 U.S. interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 13 U.S. interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 14 U.S. interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 15 U.S. interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 16 Canada interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 17 Canada interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 18 Canada interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 19 Canada interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 20 Mexico interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 21 Mexico interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 22 Mexico interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 23 Mexico interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 24 Europe interleukin inhibitors market, by country, 2018 - 2030 (USD Million)
Table 25 Europe interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 26 Europe interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 27 Europe interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 28 Europe interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 29 UK interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 30 UK interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 31 UK interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 32 UK interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 33 Germany interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 34 Germany interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 35 Germany interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 36 Germany interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 37 France interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 38 France interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 39 France interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 40 France interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 41 Italy interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 42 Italy interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 43 Italy interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 44 Italy interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 45 Denmark interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 46 Denmark interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 47 Denmark interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 48 Denmark interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 49 Spain interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 50 Spain interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 51 Spain interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 52 Spain interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 53 Sweden interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 54 Sweden interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 55 Sweden interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 56 Sweden interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 57 Norway interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 58 Norway interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 59 Norway interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 60 Norway interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 61 Asia Pacific interleukin inhibitors market, by country, 2018 - 2030 (USD Million)
Table 62 Asia Pacific interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 63 Asia Pacific interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 64 Asia Pacific interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 65 Asia Pacific interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 66 Japan interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 67 Japan interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 68 Japan interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 69 Japan interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 70 China interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 71 China interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 72 China interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 73 China interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 74 India interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 75 India interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 76 India interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 77 India interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 78 Australia interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 79 Australia interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 80 Australia interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 81 Australia interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 82 South Korea interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 83 South Korea interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 84 South Korea interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 85 South Korea interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 86 Thailand interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 87 Thailand interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 88 Thailand interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 89 Thailand interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 90 Latin America interleukin inhibitors market, by country, 2018 - 2030 (USD Million)
Table 91 Latin America interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 92 Latin America interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 93 Latin America interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 94 Latin America interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 95 Brazil interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 96 Brazil interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 97 Brazil interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 98 Brazil interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 99 Argentina interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 100 Argentina interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 101 Argentina interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 102 Argentina interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 103 Middle East & Africa interleukin inhibitors market, by country, 2018 - 2030 (USD Million)
Table 104 Middle East & Africa interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 105 Middle East & Africa interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 106 Middle East & Africa interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 107 Middle East & Africa interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 108 South Africa interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 109 South Africa interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 110 South Africa interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 111 South Africa interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 112 Saudi Arabia interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 113 Saudi Arabia interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 114 Saudi Arabia interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 115 Saudi Arabia interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 116 UAE interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 117 UAE interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 118 UAE interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 119 UAE interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 120 Kuwait interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
Table 121 Kuwait interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
Table 122 Kuwait interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
Table 123 Kuwait interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Interleukin inhibitors market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Segment outlook (USD Million)
Fig. 10 Segment outlook (USD Million)
Fig. 11 Competitive landscape
Fig. 12 Interleukin inhibitors market dynamics
Fig. 13 Interleukin inhibitors market: Porter’s five forces analysis
Fig. 14 Interleukin inhibitors market: PESTLE analysis
Fig. 15 Interleukin inhibitors market: Type segment dashboard
Fig. 16 Interleukin inhibitors market: Type market share analysis, 2024 & 2030
Fig. 17 IL-1 inhibitors market, 2018 - 2030 (USD Million)
Fig. 18 IL-2 inhibitors market, 2018 - 2030 (USD Million)
Fig. 19 IL-5 inhibitors market, 2018 - 2030 (USD Million)
Fig. 20 IL-6 inhibitors market, 2018 - 2030 (USD Million)
Fig. 21 IL-17 inhibitors market, 2018 - 2030 (USD Million)
Fig. 22 IL-23 inhibitors market, 2018 - 2030 (USD Million)
Fig. 23 Others market, 2018 - 2030 (USD Million)
Fig. 24 Interleukin inhibitors market: Route of administration segment dashboard
Fig. 25 Interleukin inhibitors market: Route of administration market share analysis, 2024 & 2030
Fig. 26 Subcutaneous (SC) market, 2018 - 2030 (USD Million)
Fig. 27 Intravenous (IV) market, 2018 - 2030 (USD Million)
Fig. 28 Interleukin inhibitors market: Application segment dashboard
Fig. 29 Interleukin inhibitors market: Application market share analysis, 2024 & 2030
Fig. 30 Rheumatoid arthritis market, 2018 - 2030 (USD Million)
Fig. 31 Psoriasis market, 2018 - 2030 (USD Million)
Fig. 32 Inflammatory bowel disease (IBD) market, 2018 - 2030 (USD Million)
Fig. 33 Asthma market, 2018 - 2030 (USD Million)
Fig. 34 Others market, 2018 - 2030 (USD Million)
Fig. 35 Interleukin inhibitors market: End use segment dashboard
Fig. 36 Interleukin inhibitors market: End use market share analysis, 2024 & 2030
Fig. 37 Hospitals market, 2018 - 2030 (USD Million)
Fig. 38 Specialty clinics market, 2018 - 2030 (USD Million)
Fig. 39 Others market, 2018 - 2030 (USD Million)
Fig. 40 Interleukin inhibitors market revenue, by region
Fig. 41 Regional marketplace: Key takeaways
Fig. 42 Regional marketplace: Key takeaways
Fig. 43 North America interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 44 U.S. country dynamics
Fig. 45 U.S. interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 46 Canada country dynamics
Fig. 47 Canada interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 48 Mexico country dynamics
Fig. 49 Mexico interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 50 Europe interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 51 UK country dynamics
Fig. 52 UK interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 53 Germany country dynamics
Fig. 54 Germany interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 55 France country dynamics
Fig. 56 France interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 57 Italy country dynamics
Fig. 58 Italy interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 59 Spain country dynamics
Fig. 60 Spain interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 61 Norway country dynamics
Fig. 62 Norway interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 63 Sweden country dynamics
Fig. 64 Sweden interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 65 Denmark country dynamics
Fig. 66 Denmark interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 67 Asia Pacific interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 68 Japan country dynamics
Fig. 69 Japan interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 70 China country dynamics
Fig. 71 China interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 72 India country dynamics
Fig. 73 India interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 74 Australia country dynamics
Fig. 75 Australia interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 76 South Korea country dynamics
Fig. 77 South Korea interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 78 Thailand country dynamics
Fig. 79 Thailand interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 80 Latin America interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 81 Brazil country dynamics
Fig. 82 Brazil interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 83 Argentina country dynamics
Fig. 84 Argentina interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 85 MEA interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 86 South Africa country dynamics
Fig. 87 South Africa interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 88 Saudi Arabia country dynamics
Fig. 89 Saudi Arabia interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 90 UAE country dynamics
Fig. 91 UAE interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 92 Kuwait country dynamics
Fig. 93 Kuwait interleukin inhibitors market, 2018 - 2030 (USD Million)
Fig. 94 Company categorization
Fig. 95 Company market position analysis
Fig. 96 Strategic framework

Companies Mentioned

  • Novartis AG
  • AbbVie Inc.
  • Eli Lilly and Company
  • Regeneron Pharmaceuticals Inc.
  • Johnson & Johnson Services, Inc.
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca
  • Bausch Health Companies Inc.
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd

Methodology

Loading
LOADING...

Related Topics

Related Reports

InterLeukin6 IL6 Inhibitor Market 2024 - Product Image

InterLeukin6 IL6 Inhibitor Market 2024

  • Report
  • 175 Pages
  • Global
From
Interleukin Inhibitors Market Report and Forecast 2024-2032 - Product Image

Interleukin Inhibitors Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From
Interleukin Inhibitors Global Market Report 2024 - Product Image

Interleukin Inhibitors Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From
Interleukin-33 inhibitors - Pipeline Insight, 2024 - Product Image

Interleukin-33 inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • 60 Pages
  • Global
From
Interleukin-13 (IL-13) Inhibitor - Pipeline Insight, 2024 - Product Image

Interleukin-13 (IL-13) Inhibitor - Pipeline Insight, 2024

  • Drug Pipelines
  • 60 Pages
  • Global
From

About the Interleukin Inhibitor Market

Interleukin inhibitors are a type of immune disorder drug used to treat a variety of conditions, including rheumatoid arthritis, psoriasis, and Crohn's disease. These drugs work by blocking the action of interleukins, which are proteins that play a role in inflammation and the body's immune response. Interleukin inhibitors can be used alone or in combination with other drugs to reduce inflammation and improve symptoms. The interleukin inhibitor market is a rapidly growing segment of the immune disorder drug market. It is expected to continue to grow as more treatments become available and as the demand for treatments for immune-related conditions increases. Some of the major companies in the interleukin inhibitor market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, and Pfizer. These companies are actively researching and developing new treatments for immune-related conditions. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.